Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant decline in short interest in March. As of March 13th, there was short interest totaling 160,544 shares, a decline of 68.6% from the February 26th total of 510,812 shares. Based on an average daily trading volume, of 845,133 shares, the short-interest ratio is presently 0.2 days. Approximately 6.3% of the shares of the company are short sold.

Cardio Diagnostics Trading Up 4.4%

NASDAQ CDIO traded up $0.08 on Friday, hitting $1.96. 52,230 shares of the company were exchanged, compared to its average volume of 4,199,352. Cardio Diagnostics has a 1-year low of $0.97 and a 1-year high of $17.39. The firm has a 50 day moving average of $2.67 and a two-hundred day moving average of $3.23. The company has a market cap of $5.81 million, a P/E ratio of -0.53 and a beta of 2.28.

Cardio Diagnostics (NASDAQ:CDIO) last announced its earnings results on Friday, March 13th. The company reported ($0.80) earnings per share for the quarter. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%. Research analysts anticipate that Cardio Diagnostics will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Cardio Diagnostics to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cardio Diagnostics presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cardio Diagnostics stock. DRW Securities LLC lifted its position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,463 shares of the company’s stock after acquiring an additional 22,298 shares during the quarter. DRW Securities LLC owned approximately 2.21% of Cardio Diagnostics worth $110,000 at the end of the most recent reporting period. 8.06% of the stock is owned by hedge funds and other institutional investors.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.